Download REFERÊNCIAS 1. Barsky AJ, Orav EJ, Bates DW

REFERÊNCIAS
1. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs
independent of psychiatric and medical comorbidity. Arch Gen Psychiatry.
2005;62(8):903-10.
2. Kellner R, Sheffield BF. The one-week prevalence of symptoms in neurotic patients
and normals. Am J Psychiatry. 1973;130(1):102-5.
3. Kroenke K, Spitzer RL, Williams JB, Linzer M, Hahn SR, deGruy FV 3rd, et al.
Physical symptoms in primary care. Predictors of psychiatric disorders and functional
impairment. Arch Fam Med. 1994;3(9):774-9.
4. Lipowski ZJ. Somatization: the concept and its clinical application. Am J Psychiatry.
1988;145(11):1358-68.
5. Kirmayer LJ, Robbins JM. Currents concepts of somatization: research and clinical
perspective. Washington: American Psychiatric Press; 1991.
6. Fortes S. Transtornos mentais na atenção primária: suas formas de apresentação,
perfil nosológico e fatores associados em unidades do programa de saúde da família do
município de Petrópolis. Rio de Janeiro; 2004.
7. Goldberg DP, Huxley P. Common mental disorders: a bio-social model. London:
Routledge; 1992.
8. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study
of the relation between somatic symptoms and depression. N Engl J Med.
1999;341(18):1329-35.
9. Ring A, Dowrick CF, Humphris GM, Davies J, Salmon P. The somatising effect of
clinical consultation: what patients and doctors say and do not say when patients present
medically unexplained physical symptoms. Soc Sci Med. 2005;61(7):1505-15.
10. Ring A, Dowrick C, Humphris G, Salmon P. Do patients with unexplained physical
symptoms pressurise general practitioners for somatic treatment? A qualitative study.
BMJ. 2004;328(7447):1057.
11. Üstün TB, Sartorius N. Mental illness in general health care: an international study.
Chichester: John Wiley & Sons; 1995.
12. Reilly J, Baker GA, Rhodes J, Salmon P. The association of sexual and physical
abuse with somatization: characteristics of patients presenting with irritable bowel
syndrome and non-epileptic attack disorder. Psychol Med. 1999;29(2):399-406.
13. Helman CG. Cultura, saúde e doença. 2. ed. Porto Alegre: Artmed; 2005.
14. Goldberg DP, Gask L, Sartorius N. A general introduction to training physicians in
mental health skills. Geneva: WPA; 2001.
15. TóFoli LF, Fortes S, Gonçalves D, Chazan LF, Ballester D. Somatização e sintomas
físicos inexplicáveis para o médico de família e comunidade. Programa de Atualização
em Medicina de Família e Comunidade. 2007;2(3):9-56.
16. Fortes S, Brasil MAA, Garcia-Campayo J, Botega NJ. Somatização. In: Prática
psiquiátrica no hospital geral: interconsulta e emergência. Porto Alegre: Artmed; 2005.
17. TóFoli LF. Transtornos somatoformes, síndromes funcionais e sintomas físicos sem
explicação médica. In: Lopes AC, organizador. Tratado de clínica médica. São Paulo:
Rocca; 2006. p. 2504-12.
18. Jacob KS. A simple protocol to manage patients with unexplained somatic
symptoms in medical practice. Natl Med J India. 2004;17(6):326-8.
19. American Psychiatric Association. Diagnostic and statistical manual of mental
disorders: DSM-III. 3rd ed. Washington: American Psychiatric Association; 1980.
20. Organização Mundial da Saúde. Classificação de transtornos mentais e de
comportamento da CID-10. 10. ed. Porto Alegre: Artmed; 1993.
21. American Psychiatric Association. Diagnostic and statistical manual of mental
disorders: DSM-IV-TR. Washington: American Psychiatric Association; 2000.
22. Sharpe M, Carson A. “Unexplained” somatic symptoms, functional syndromes, and
somatization: do we need a paradigm shift? Ann Intern Med. 2001;134(9 Pt 2):926-30.
23. Mayou R, Kirmayer LJ, Simon G, Kroenke K, Sharpe M. Somatoform disorders:
time for a new approach in DSM-V. Am J Psychiatry. 2005;162(5):847-855.
24. Larisch A, Schweickhardt A, Wirsching M, Fritzsche K. Psychosocial interventions
for somatizing patients by the general practitioner: a randomized controlled trial. J
Psychosom Res. 2004;57(6):507-14; discussion 515-6.
25. World Health Organization. Mental health gap intervention guide for mental,
neurological and substance use disorders in non-specialized health settings [Internet].
Geneva: WHO; 2010 [capturado em 01 nov. 2010]. Disponível em:
http://whqlibdoc.who.int/publications/2010/9789241548069_eng.pdf.
26. Smith RC, Gardiner JC, Luo Z, Schooley S, Lamerato L, Rost K. Primary care
physicians treat somatization. J Gen Intern Med. 2009;24(7):829-32.
27. García-Campayo J, Claraco Vega LM, Tazón P, Aseguinolaza L. Problem-solving
therapy: the psychotherapy of choice for primary care. Aten Primaria. 1999;24(10):594601. Spanish.
28. Lidbeck J. Group therapy for somatization disorders in general practice:
effectiveness of a short cognitive-behavioural treatment model. Acta Psychiatr Scand.
1997;96(1):14-24.
29. Huibers MJH, Beurskens AJHM, Bleijenberg G, van Schayck CP. Psychosocial
interventions by general practitioners. Cochrane Database Syst Rev.
2007;(3):CD003494.
30. Araya R, Rojas G, Fritsch R, Gaete J, Rojas M, Simon G, et al. Treating depression
in primary care in low-income women in Santiago, Chile: a randomised controlled trial.
Lancet. 2003;361(9362):995-1000.
31. Sim J, Adams N. Systematic review of randomized controlled trials of
nonpharmacological interventions for fibromyalgia. Clin J Pain. 2002;18(5):324-36.
32. Fortes S, Baptista CMA. Família e somatização: entendendo suas interações. In:
Mello Filho J de, Burd M, organizadores. Doença e família. São Paulo: Casa do
Psicólogo; 2004. p. 259-84.
33. Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized
controlled trials. Psychosom Med. 2007;69(9):881-8.
34. Mayou R. Are treatments for common mental disorders also effective for functional
symptoms and disorder? Psychosom Med. 2007;69(9):876-80.
35. Luo Y-L, Zhang M-Y, Wu W-Y, Li C-B, Lu Z, Li Q-W. A randomized doubleblind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain
disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1522-5.
36. Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, et al.
Randomised controlled trial to determine the clinical effectiveness and costeffectiveness of selective serotonin reuptake inhibitors plus supportive care, versus
supportive care alone, for mild to moderate depression with somatic symptoms in
primary care: the THREAD (THREshold for AntiDepressant response) study. Health
Technol Assess. 2009;13(22):iii-iv, ix-xi, 1-159.
37. Muller JE, Wentzel I, Koen L, Niehaus DJH, Seedat S, Stein DJ. Escitalopram in
the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. Int
Clin Psychopharmacol. 2008;23(1):43-8.
38. Han C, Pae C-U, Lee B-H, Ko Y-H, Masand PS, Patkar AA, et al. Venlafaxine
versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week
prospective, open-label, randomized, parallel-group trial. Clin Drug Investig.
2008;28(4):251-61.
39. Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A, Conte A, et al.
Randomized double-blind comparison of serotonergic (Citalopram) versus
noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSMIV-TR pain disorder. Eur J Pain. 2005;9(1):33-8.
40. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Do antidepressants have an
analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis.
Psychosom Med. 1998;60(4):503-9.
41. Rouillon F, Rahola G, Van Moffaert M, Lopes RG, Dunia I. Sulpiride in the
treatment of somatoform disorders: results of a European observational study to
characterize the responder profile. J Int Med Res. 2001;29(4):304-13.
42. Ferreri M, Florent C, Gerard D. Sulpiride: study of 669 patient presenting with pain
of psychological origin. Encephale. 2000;26(4):58-66. French.
43. Altamura AC, Mauri MC, Regazzetti G, Coppola MT. L-sulpiride in the treatment
of somatoform disturbances: a double-blind study with racemic sulpiride. Minerva
Psichiatr. 1991;32(1):25-9. Italian.
44. Kroenke K, Swindle R. Cognitive-behavioral therapy for somatization and symptom
syndromes: a critical review of controlled clinical trials. Psychother Psychosom.
2000;69(4):205-15.
45. García-Campayo J, Arevalo E, Claraco LM, Alda M, Lopez del Hoyo Y. A
prevention programme for somatoform disorders is effective for affective disorders. J
Affect Disord. 2010;122(1-2):124-32.
46. Sumathipala A. What is the evidence for the efficacy of treatments for somatoform
disorders? A critical review of previous intervention studies. Psychosom Med.
2007;69(9):889-900.
47. Creed F, Tomenson B, Guthrie E, Ratcliffe J, Fernandes L, Read N, et al. The
relationship between somatisation and outcome in patients with severe irritable bowel
syndrome. J Psychosom Res. 2008;64(6):613-20.
48. Abbass A, Kisely S, Kroenke K. Short-term psychodynamic psychotherapy for
somatic disorders. Psychother Psychosom. 2009;78(5):265-74.